Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03450135 · ClinicalTrials.gov registry record

Neurophysiology, Estrogen, and Stress Exposure in the Emergence of Depression in Adolescent Girls

A clinical trial of Stress and Adolescent Development, sponsored by University of North Carolina, Chapel Hill.

Completed
Registry status
53
Enrollment target
1
Study location

NCT03450135: Completed study of Stress and Adolescent Development, sponsored by University of North Carolina, Chapel Hill.

NCT03450135 is a study of Stress and Adolescent Development that has completed, run by University of North Carolina, Chapel Hill. The registered enrollment target is 53 participants, below the 786-participant average among 152 other Stress trials with a reported enrollment target (93% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03450135, a study of Stress and Adolescent Development, has completed, sponsored by University of North Carolina, Chapel Hill.

COMPLETED
Registry status
53 participants
Enrollment target
1
Study location

Study Summary

The prevalence of adolescent depression is steadily rising in the U.S., especially among adolescent girls. Currently 20% of adolescent girls experience major depression compared with 6% of boys (National Institute of Mental Health, 2016). The profound gender disparity in depression that emerges at puberty, but not before, implicates a role of ovarian steroid hormones in promoting affective (mood) symptoms in adolescent girls. In addition to dramatic physical maturation and a rapidly changing reproductive hormone environment at puberty, adolescence is also a time of exposure to substantial psychosocial stress, particularly in girls. It is well documented that stress interferes with the maturation of neurodevelopmental trajectories and is a critical precipitating factor in the pathway to psychopathology. However, the neuropathophysiological mechanisms linking stress exposure and sensitivity to ovarian hormone fluctuations at puberty to the onset and maintenance of depression symptoms in adolescence have yet to be elucidated, and is the purpose of this research.

Primary Outcome

The MFQ consists of 33 descriptive phrases regarding how the subject has been feeling or acting recently (past two weeks) on a 3-point force-choice Likert-type response scales (most of the time, sometimes, or not at all). Greater scores reflect greater symptom severity.

Interventions

  • BEHAVIORAL Trier Social Stress Test
  • BEHAVIORAL Emotional go/no-go task

Study Locations (1)

North Carolina

  • University of North Carolina, SHARRP Lab - Chapel Hill

Trial Details

FieldValue
Enrollment Target 53 participants
Start Date 2018-02-25
Est. Completion 2020-06-30

What the finished NCT03450135 record still lists

NCT03450135 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 53 participants, a relatively small participant target, below the 786-participant average among 152 other Stress trials with a reported enrollment target (93% lower).

The record links to 3 conditions, with Stress appearing as the primary indexed condition, and to 2 interventions - of which Trier Social Stress Test is the first listed.

NCT03450135 reports a single indexed study location in North Carolina.

Frequently Asked Questions

What is clinical trial NCT03450135 about?

NCT03450135 is a clinical study titled "Neurophysiology, Estrogen, and Stress Exposure in the Emergence of Depression in Adolescent Girls". The prevalence of adolescent depression is steadily rising in the U.S., especially among adolescent girls. Currently 20% of adolescent girls experience major depression compared with 6% of boys (National Institute of Mental Health, 2016). The profound gender disparity in depression that emerges at p...

What is the current status of trial NCT03450135?

This trial is currently completed. The enrollment target is 53 participants. The study started on 2018-02-25. Estimated completion is 2020-06-30.

What conditions does trial NCT03450135 study?

This clinical trial studies the following conditions: Stress, Adolescent Development, Emotional Disturbances.

What interventions are being tested in trial NCT03450135?

The interventions under investigation include: Trier Social Stress Test (BEHAVIORAL), Emotional go/no-go task (BEHAVIORAL).

Who is sponsoring clinical trial NCT03450135?

This trial is sponsored by University of North Carolina, Chapel Hill, which has 1,109 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03450135 being conducted?

This trial has 1 study location across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Stress

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT03450135's enrollment target sits among peer trials

53 99th of 152 higher than 50 of 152 other Stress trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Stress trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT04177004 · 53 participants · Phase 1

    Human Lysozyme Goat Milk for the Prevention of Graft Versus Host Disease in Patients With Blood Cancer Undergoing a Donor Stem Cell Transplant

  • NCT04199741 · 53 participants · Phase 1

    PET/CT Imaging of Small Cell Lung Cancer Using 89Zr-DFO-SC16.56

  • NCT04835129 · 53 participants · Phase 2

    Isatuximab, Pomalidomide, Elotuzumab and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma

  • NCT04913805 · 53 participants · Phase 2

    Matching Perfusion and Metabolic Activity in HFpEF

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT03450135, the US trial registry maintained by the National Library of Medicine. NCT03450135 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.